Loss of neprilysin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy
about
Transthyretin and the brain re-visited: is neuronal synthesis of transthyretin protective in Alzheimer's disease?ApoE promotes the proteolytic degradation of AbetaImpaired vascular-mediated clearance of brain amyloid beta in Alzheimer's disease: the role, regulation and restoration of LRP1Intracellular cleavage of amyloid β by a viral protease NIa prevents amyloid β-mediated cytotoxicityRegulation of distinct pools of amyloid β-protein by multiple cellular proteasesIn vitro Pb exposure disturbs the balance between Aβ production and elimination: the role of AβPP and neprilysinNeprilysin overexpression inhibits plaque formation but fails to reduce pathogenic Abeta oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice.Alzheimer disease models and human neuropathology: similarities and differencesAmyloid-β/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease.Nonsteroidal selective androgen receptor modulators and selective estrogen receptor β agonists moderate cognitive deficits and amyloid-β levels in a mouse model of Alzheimer's disease.Long-term neprilysin gene transfer is associated with reduced levels of intracellular Abeta and behavioral improvement in APP transgenic miceEstrogen stimulates degradation of beta-amyloid peptide by up-regulating neprilysin.Transgenic Drosophila models of Alzheimer's disease and tauopathiesThe nuclear inclusion a (NIa) protease of turnip mosaic virus (TuMV) cleaves amyloid-βNeuronal heparan sulfates promote amyloid pathology by modulating brain amyloid-β clearance and aggregation in Alzheimer's disease.Expression and functional profiling of neprilysin, insulin-degrading enzyme, and endothelin-converting enzyme in prospectively studied elderly and Alzheimer's brain.Tau-dependent Kv4.2 depletion and dendritic hyperexcitability in a mouse model of Alzheimer's disease.A combination Alzheimer's therapy targeting BACE1 and neprilysin in 5XFAD transgenic mice.Cerebral amyloid angiopathy pathology and cognitive domains in older personsExpression of the plant viral protease NIa in the brain of a mouse model of Alzheimer's disease mitigates Aβ pathology and improves cognitive functionInteractions between oestrogen and the renin angiotensin system - potential mechanisms for gender differences in Alzheimer's disease.Neprilysin: an enzyme candidate to slow the progression of Alzheimer's diseaseBrain-Wide Insulin Resistance, Tau Phosphorylation Changes, and Hippocampal Neprilysin and Amyloid-β Alterations in a Monkey Model of Type 1 Diabetes.The role of microglia in amyloid clearance from the AD brain.Rapid in vivo measurement of β-amyloid reveals biphasic clearance kinetics in an Alzheimer's mouse model.Mechanisms that lessen benefits of β-secretase reduction in a mouse model of Alzheimer's disease.Hereditary and sporadic forms of abeta-cerebrovascular amyloidosis and relevant transgenic mouse modelsDistinct subcellular patterns of neprilysin protein and activity in the brains of Alzheimer's disease patients, transgenic mice and cultured human neuronal cells.Mechanisms of Amyloid-β Peptide Clearance: Potential Therapeutic Targets for Alzheimer's Disease.The AbetaCs of Abeta-cleaving proteases.Acyl peptide hydrolase degrades monomeric and oligomeric amyloid-beta peptide.Mercury induced the Accumulation of Amyloid Beta (Aβ) in PC12 Cells: The Role of Production and Degradation of Aβ.Cerebral amyloid angiopathy in the aetiology and immunotherapy of Alzheimer disease.Pericyte loss influences Alzheimer-like neurodegeneration in mice.Epigenetic modifications of chronic hypoxia-mediated neurodegeneration in Alzheimer's disease.Proteolytic degradation of amyloid β-protein.Clearance of amyloid-β peptides by microglia and macrophages: the issue of what, when and where.Metallostasis and amyloid β-degrading enzymes.Targeting estrogen receptors for the treatment of Alzheimer's disease.Convection-enhanced drug delivery to the brain: therapeutic potential and neuropathological considerations.
P2860
Q21202832-1C8AD2B5-1726-4F19-B0E4-293FCC1F8532Q24651102-CFCEEC43-8D87-49A1-9ACE-11DAD9FA5BC6Q26800063-EB7AEC9A-6B74-48AC-8F75-70833A4B46A6Q27324934-FA3A23C3-21E0-48BC-A19B-5E9635C905BAQ27694752-39B15B37-E0B8-45FF-B34F-EAE3B56D59A7Q28388231-36DF3C6B-CDE4-4842-B295-C96C3E77C115Q30491245-140F7A74-A092-464E-BD69-156A297B25ACQ30499574-1232F2DC-C717-46A4-B932-AA7000B16686Q30513293-A9B211D2-3334-4931-9FA2-52B669175CB8Q30560110-031EEAF7-B5B1-4DF7-8C43-4550F614B7FFQ33384861-B0057DFB-3E70-4F41-83B0-771B86C48BF7Q33569877-CCEB50D1-D7AE-4481-AF44-70A6FC289E91Q33770749-6B5B1E08-81C3-461D-9760-9753283EFB84Q33781167-C5D67404-1AEF-43DC-A6B1-1592A252F575Q33908201-5F2EA838-6B01-4C1C-96E7-B6CEC8D048E5Q34130147-6314EBCC-8BE1-4948-A41A-F1D8CDE184B1Q35423803-4929E214-FFBF-4B43-996A-B3D48A93CAD1Q35426661-FA9D691D-E425-41B3-B571-8CD810996F0AQ35586025-0E4B1857-7683-4D8F-B277-6FDDE734F22FQ36514449-4034E3BD-4DC2-4228-AE6F-1A001246B0EEQ36576477-8DBB39ED-74C7-4D94-A9E3-2443B19A9C24Q36579852-90B12F01-9575-4380-8E63-E88E54F0C978Q36792589-D0FD3666-AA93-4838-86CA-28CD823C0659Q36841789-CBFA30B2-9E15-42CC-A029-2E07632DD8BFQ36863138-9A89D237-982B-40BD-837D-FD760EE0F8CAQ37065293-AD51257F-43D4-48FD-8438-5898FCDC8808Q37188278-3505C56B-F9E9-4137-A2B3-6D80E212F062Q37205562-EF0EDFE4-19C6-4C64-BDDF-C02089B70375Q37224550-54D72F48-F61A-4046-A857-705C39CDD0D7Q37250796-3DE9A086-53BF-4691-AA8F-2FAB44776738Q37303380-F068AED3-D709-4497-8AD3-37CD4E7CD260Q37605697-6AA111B5-8AA8-4BD0-B44A-0BE428D98A0DQ37613107-06206729-A9FF-436C-A852-B4461BC78EFCQ37623577-21A1C253-72A9-4DE9-AA78-77E3FF626FD1Q37714817-852D8CD8-E132-466D-80D6-9D77E513F8DCQ38016899-EB2754EC-D06D-4220-BDE0-70AC03CE7B15Q38021993-FE227553-F555-4A66-B5BE-73BE15FB409CQ38029514-17163422-9CF5-4C03-B30B-3D34D120FD75Q38114867-0D928C6B-DE9C-4418-9BFA-A2391576B237Q38128898-B0975946-707C-49C3-A106-100135E5E372
P2860
Loss of neprilysin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Loss of neprilysin function pr ...... es cerebral amyloid angiopathy
@ast
Loss of neprilysin function pr ...... es cerebral amyloid angiopathy
@en
type
label
Loss of neprilysin function pr ...... es cerebral amyloid angiopathy
@ast
Loss of neprilysin function pr ...... es cerebral amyloid angiopathy
@en
prefLabel
Loss of neprilysin function pr ...... es cerebral amyloid angiopathy
@ast
Loss of neprilysin function pr ...... es cerebral amyloid angiopathy
@en
P2093
P2860
P1476
Loss of neprilysin function pr ...... es cerebral amyloid angiopathy
@en
P2093
Ana George
Dennis J Selkoe
Dominic M Walsh
Ganesh M Shankar
John R Cirrito
Malcolm A Leissring
Sonja G Schütz
Wei Qiao Qiu
Wesley Farris
Xiaoyan Sun
P2860
P304
P356
10.2353/AJPATH.2007.070105
P407
P577
2007-07-01T00:00:00Z